Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Polski Przegląd Neurologiczny
MENU
Na skróty Zdeponuj artykuł Wytyczne dla autorów Ahead of print Recenzenci 2022

dostęp otwarty

Tom 14, Nr 3 (2018)
Artykuł przeglądowy
Opublikowany online: 2018-11-21
Pokaż PDF Pobierz plik PDF
Pobierz cytowanie

Przegląd czynników ryzyka krwotoku wewnątrzczaszkowego po dożylnym leczeniu trombolitycznym udaru niedokrwiennego mózgu

Małgorzata Wichlińska-Lubińska1
Pol. Przegl. Neurol 2018;14(3):156-164.
Afiliacje
  1. Klinika Neurologii, Szpital Uniwersytecki nr 1 im. dr A. Jurasza, Bydgoszcz

dostęp otwarty

Tom 14, Nr 3 (2018)
Artykuły przeglądowe
Opublikowany online: 2018-11-21

Streszczenie

Mimo że dożylne leczenie trombolityczne jest skutecznym i obecnie powszechnie akceptowanym sposobem postępowania w ostrej fazie udaru niedokrwiennego mózgu, zastosowanie tej metody nadal pozostaje nie w pełni wykorzystane. Jednym z ważniejszych tego powodów (poza ograniczeniami wynikającymi z protokołu leczenia) wydaje się obawa przed powikłaniami krwotocznymi, zwłaszcza wewnątrzczaszkowymi. Celem niniejszego artykułu jest zbiorcze przedstawienie badań dotyczących czynników ryzyka wewnątrzczaszkowych powikłań krwotocznych po leczeniu trombolitycznym. Analiza ma przybliżyć i uporządkować zagadnienia oraz uświadomić czytelnikom, że wyniki badań nie są jednoznaczne i nie powinny negatywnie wpływać na podejmowanie decyzji o leczeniu za pomocą rekombinowanego tkankowego aktywatora plazminogenu.

Streszczenie

Mimo że dożylne leczenie trombolityczne jest skutecznym i obecnie powszechnie akceptowanym sposobem postępowania w ostrej fazie udaru niedokrwiennego mózgu, zastosowanie tej metody nadal pozostaje nie w pełni wykorzystane. Jednym z ważniejszych tego powodów (poza ograniczeniami wynikającymi z protokołu leczenia) wydaje się obawa przed powikłaniami krwotocznymi, zwłaszcza wewnątrzczaszkowymi. Celem niniejszego artykułu jest zbiorcze przedstawienie badań dotyczących czynników ryzyka wewnątrzczaszkowych powikłań krwotocznych po leczeniu trombolitycznym. Analiza ma przybliżyć i uporządkować zagadnienia oraz uświadomić czytelnikom, że wyniki badań nie są jednoznaczne i nie powinny negatywnie wpływać na podejmowanie decyzji o leczeniu za pomocą rekombinowanego tkankowego aktywatora plazminogenu.

Pełny tekst:

Pokaż PDF Pobierz plik PDF
Pobierz cytowanie

Słowa kluczowe

czynniki ryzyka; udar niedokrwienny mózgu; leczenie trombolityczne; krwotok wewnątrzczaszkowy

Informacje o artykule
Tytuł

Przegląd czynników ryzyka krwotoku wewnątrzczaszkowego po dożylnym leczeniu trombolitycznym udaru niedokrwiennego mózgu

Czasopismo

Polski Przegląd Neurologiczny

Numer

Tom 14, Nr 3 (2018)

Typ artykułu

Artykuł przeglądowy

Strony

156-164

Opublikowany online

2018-11-21

Wyświetlenia strony

886

Wyświetlenia/pobrania artykułu

1816

Rekord bibliograficzny

Pol. Przegl. Neurol 2018;14(3):156-164.

Słowa kluczowe

czynniki ryzyka
udar niedokrwienny mózgu
leczenie trombolityczne
krwotok wewnątrzczaszkowy

Autorzy

Małgorzata Wichlińska-Lubińska

Referencje (104)
  1. Jauch EC, Saver JL, Adams HP, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3): 870–947.
    CrossRefPubMed
  2. Śledzińska-Dźwigał M, Kobayashi A, Członkowska A, et al. Czynniki ryzyka wewnątrzczaszkowych powikłań krwotocznych związanych z leczeniem trombolitycznym udaru niedokrwiennego mózgu. Terapia. 2012; 1: 14–20.
  3. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke. 2001; 32(6): 1330–1335.
    CrossRefPubMed
  4. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke. 2006; 37(2): 556–561.
    CrossRefPubMed
  5. Paszkiewicz-Woźniak D. Postępowanie w przypadku powikłań leczenia trombolitycznego udaru niedokrwiennego mózgu. Neurologia po Dyplomie. 2014; 9(6): 25–48.
  6. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med. 1995; 333(24): 1581–1588.
    CrossRef
  7. The National Institute of Neurological Disorders and rt-PA Study Group.. Intracerebral Hemorrhage After Intravenous t-PA Therapy for Ischemic Stroke. Stroke. 1997; 28(11): 2109–2118.
    CrossRef
  8. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13): 1017–1025.
    CrossRefPubMed
  9. Hacke W, Kaste M, Fieschi C, et al. Second European-Australasian Acute Stroke Study Investigators.. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 352(9136): 1245–1251.
    CrossRefPubMed
  10. Wahlgren N, Ahmed N, Eriksson N, et al. Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008; 39(12): 3316–3322.
    CrossRefPubMed
  11. Seet RCS, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions. Cerebrovasc Dis. 2012; 34(2): 106–114.
    CrossRefPubMed
  12. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatry. 2008; 79(10): 1093–1099.
    CrossRefPubMed
  13. Rubiera M, Alvarez-Sabín J, Ribo M, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005; 36(7): 1452–1456.
    CrossRefPubMed
  14. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999; 282(21): 2019–2026.
    CrossRefPubMed
  15. Hacke W, Kaste M, Bluhmki E, et al. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13): 1317–1329.
    CrossRefPubMed
  16. Hacke W, Donnan G, Fieschi C, et al. ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004; 363(9411): 768–774.
    CrossRefPubMed
  17. Thomalla G, Sobesky J, Köhrmann M, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007; 38(2): 313–318.
    CrossRefPubMed
  18. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002; 105(14): 1679–1685.
    CrossRefPubMed
  19. Lansberg MG, Albers GW, Wijman CAC. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007; 24(1): 1–10.
    CrossRefPubMed
  20. Cocho D, Borrell M, Martí-Fàbregas J, et al. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke. 2006; 37(4): 996–999.
    CrossRefPubMed
  21. Heuschmann PU, Kolominsky-Rabas PL, Roether J, et al. German Stroke Registers Study Group. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA. 2004; 292(15): 1831–1838.
    CrossRefPubMed
  22. Simon JE, Sandler DL, Pexman JH, et al. Calgary Stroke Programme. Is intravenous recombinant tissue plasminogen activator (rt-PA) safe for use in patients over 80 years old with acute ischaemic stroke? The Calgary experience. Age Ageing. 2004; 33(2): 143–149.
    CrossRefPubMed
  23. Berrouschot J, Röther J, Glahn J, et al. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or = 80 years) stroke patients. Stroke. 2005; 36(11): 2421–2425.
    CrossRefPubMed
  24. Mouradian MS, Senthilselvan A, Jickling G, et al. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry. 2005; 76(9): 1234–1237.
    CrossRefPubMed
  25. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age — a systematic review across cohort studies. Age Ageing. 2006; 35(6): 572–580.
    CrossRefPubMed
  26. Sylaja PN, Cote R, Buchan AM, et al. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry. 2006; 77(7): 826–829.
    CrossRefPubMed
  27. Pundik S, McWilliams-Dunnigan L, Blackham KL, et al. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke. J Stroke Cerebrovasc Dis. 2008; 17(5): 266–272.
    CrossRefPubMed
  28. Sarikaya H. Safety and efficacy of thrombolysis with intravenous alteplase in older stroke patients. Drugs Aging. 2013; 30(4): 227–234.
    CrossRefPubMed
  29. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997; 28(5): 957–960.
    CrossRefPubMed
  30. Jaillard A, Cornu C, Durieux A, et al. MAST-E Group. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. Stroke. 1999; 30(7): 1326–1332.
    CrossRefPubMed
  31. Derex L, Hermier M, Adeleine P, et al. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry. 2005; 76(1): 70–75.
    CrossRefPubMed
  32. Cucchiara B, Kasner SE, Tanne D, et al. SAINT Investigators. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke. 2009; 40(9): 3067–3072.
    CrossRefPubMed
  33. Hill MD, Buchan AM. Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ. 2005; 172(10): 1307–1312.
    CrossRefPubMed
  34. Derex L, Nighoghossian N, Hermier M, et al. Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator. Stroke. 2003; 34(2): 458–463.
    CrossRefPubMed
  35. Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke. 2005; 36(3): 602–606.
    CrossRefPubMed
  36. Gilligan AK, Markus R, Read S, et al. Australian Streptokinase Trial Investigators. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke. 2002; 33(9): 2236–2242.
    CrossRefPubMed
  37. Larrue V, von Kummer R R, Müller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke. 2001; 32(2): 438–441.
    CrossRefPubMed
  38. Seet RCS, Zhang Yi, Wijdicks EF, et al. Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis. Arch Neurol. 2011; 68(11): 1454–1458.
    CrossRefPubMed
  39. Uyttenboogaart M, Koch MW, Koopman K, et al. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008; 65(5): 607–611.
    CrossRefPubMed
  40. Schmülling S, Rudolf J, Strotmann-Tack T, et al. Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2003; 16(3): 183–190.
    CrossRefPubMed
  41. Bravo Y, Martí-Fàbregas J, Cocho D, et al. Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis. Cerebrovasc Dis. 2008; 26(2): 126–133.
    CrossRefPubMed
  42. Prabhakaran S, Rivolta J, Vieira JR, et al. Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2010; 67(5): 559–563.
    CrossRefPubMed
  43. Ruecker M, Matosevic B, Willeit P, et al. Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology. 2012; 79(1): 31–38.
    CrossRefPubMed
  44. Kim YD, Lee JH, Jung YoH, et al. Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use. J Neurol Sci. 2010; 298(1–2): 101–105.
    CrossRefPubMed
  45. Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke. 2010; 41(7): 1450–1458.
    CrossRefPubMed
  46. Vergouwen MDI, Casaubon LK, Swartz RH, et al. Investigators of the Registry of the Canadian Stroke Network. Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator. Stroke. 2011; 42(4): 1041–1045.
    CrossRefPubMed
  47. Alexandrov AV, Demchuk AM, Burgin WS, et al. CLOTBUST Investigators. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000; 31(8): 1812–1816.
    CrossRefPubMed
  48. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003; 34(12): 2847–2850.
    CrossRefPubMed
  49. Martí-Fàbregas J, Bravo Y, Cocho D, et al. Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials. Cerebrovasc Dis. 2007; 23(2–3): 85–90.
    CrossRefPubMed
  50. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283(9): 1145–1150.
    CrossRefPubMed
  51. Aleu A, Mellado P, Lichy C, et al. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke. 2007; 38(2): 417–422.
    CrossRefPubMed
  52. Levy DE, Brott TG, Haley EC, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994; 25(2): 291–297.
    CrossRefPubMed
  53. Hacke W, Albers G, Al-Rawi Y, et al. DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005; 36(1): 66–73.
    CrossRefPubMed
  54. Haley EC, Lyden PD, Johnston KC, et al. TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005; 36(3): 607–612.
    CrossRefPubMed
  55. Barber PA, Demchuk AM, Zhang J, et al. ASPECTS Study Group. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. Lancet. 2000; 355(9216): 1670–1674.
    CrossRefPubMed
  56. Patel SC, Levine SR, Tilley BC, et al. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. 2001; 286(22): 2830–2838.
    CrossRefPubMed
  57. Roberts HC, Dillon WP, Furlan AJ, et al. Computed tomographic findings in patients undergoing intra-arterial thrombolysis for acute ischemic stroke due to middle cerebral artery occlusion: results from the PROACT II trial. Stroke. 2002; 33(6): 1557–1565.
    CrossRefPubMed
  58. del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry. 1998; 65(1): 1–9.
    CrossRefPubMed
  59. Dubey N, Bakshi R, Wasay M, et al. Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke. J Neuroimaging. 2001; 11(2): 184–188.
    CrossRefPubMed
  60. Lyden P. Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator. Stroke. 2003; 34(3): 821–822.
    CrossRefPubMed
  61. Wardlaw JM, Sandercock P, Lindley RI. IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. The Lancet. 2012; 379(9834): 2352–2363.
    CrossRef
  62. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. MR Stroke Group. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke. 2006; 37(10): 2463–2466.
    CrossRefPubMed
  63. Palumbo V, Boulanger JM, Hill MD, et al. CASES Investigators. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology. 2007; 68(13): 1020–1024.
    CrossRefPubMed
  64. Tisserand M, Le Guennec L, Touzé E, et al. Prevalence of MRI-defined recent silent ischemia and associated bleeding risk with thrombolysis. Neurology. 2011; 76(15): 1288–1295.
    CrossRefPubMed
  65. Lyerly MJ, Houston JT, Boehme AK, et al. Safety of intravenous tissue plasminogen activator administration with computed tomography evidence of prior infarction. J Stroke Cerebrovasc Dis. 2014; 23(6): 1657–1661.
    CrossRefPubMed
  66. Lindley RI, Wardlaw JM, Whiteley WN, et al. IST-3 Collaborative Group. Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial. Stroke. 2015; 46(3): 746–756.
    CrossRefPubMed
  67. Tong DC, Adami A, Moseley ME, et al. Relationship between apparent diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke. Stroke. 2000; 31(10): 2378–2384.
    CrossRefPubMed
  68. Tong D, Adami A, Moseley M, et al. Prediction of Hemorrhagic Transformation Following Acute Stroke. Archives of Neurology. 2001; 58(4): 587–593.
    CrossRef
  69. Selim M, Fink JN, Kumar S, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke. 2002; 33(8): 2047–2052.
    CrossRefPubMed
  70. Singer OC, Kurre W, Humpich MC, et al. MR Stroke Study Group Investigators. Risk assessment of symptomatic intracerebral hemorrhage after thrombolysis using DWI-ASPECTS. Stroke. 2009; 40(8): 2743–2748.
    CrossRefPubMed
  71. Albers GW, Thijs VN, Wechsler L, et al. DEFUSE Investigators. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006; 60(5): 508–517.
    CrossRefPubMed
  72. Vo KD, Santiago F, Lin W, et al. MR imaging enhancement patterns as predictors of hemorrhagic transformation in acute ischemic stroke. AJNR Am J Neuroradiol. 2003; 24(4): 674–679.
    CrossRefPubMed
  73. Kim EY, Na DG, Kim SS, et al. Prediction of hemorrhagic transformation in acute ischemic stroke: role of diffusion-weighted imaging and early parenchymal enhancement. AJNR Am J Neuroradiol. 2005; 26(5): 1050–1055.
    PubMed
  74. Latour LL, Kang DW, Ezzeddine MA, et al. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol. 2004; 56(4): 468–477.
    CrossRefPubMed
  75. Kassner A, Roberts T, Taylor K, et al. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol. 2005; 26(9): 2213–2217.
    PubMed
  76. Alsop DC, Makovetskaya E, Kumar S, et al. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke. 2005; 36(4): 746–750.
    CrossRefPubMed
  77. Warach S, Latour LL. Evidence of reperfusion injury, exacerbated by thrombolytic therapy, in human focal brain ischemia using a novel imaging marker of early blood-brain barrier disruption. Stroke. 2004; 35(11, Suppl 1): 2659–2661.
    CrossRefPubMed
  78. Hermier M, Nighoghossian N, Derex L, et al. Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator. J Cereb Blood Flow Metab. 2003; 23(11): 1362–1370.
    CrossRefPubMed
  79. Ohta H, Nakano S, Yokogami K, et al. Appearance of early venous filling during intra-arterial reperfusion therapy for acute middle cerebral artery occlusion: a predictive sign for hemorrhagic complications. Stroke. 2004; 35(4): 893–898.
    CrossRefPubMed
  80. Nighoghossian N, Hermier M, Adeleine P, et al. Old microbleeds are a potential risk factor for cerebral bleeding after ischemic stroke: a gradient-echo T2*-weighted brain MRI study. Stroke. 2002; 33(3): 735–742.
    CrossRefPubMed
  81. Fan YuH, Zhang L, Lam WWM, et al. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke. 2003; 34(10): 2459–2462.
    CrossRefPubMed
  82. Chalela JA, Kang DW, Warach S. Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging. 2004; 14(1): 54–57.
    CrossRefPubMed
  83. Derex L, Nighoghossian N, Hermier M, et al. Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis. 2004; 17(2–3): 238–241.
    CrossRefPubMed
  84. Kakuda W, Thijs VN, Lansberg MG, et al. DEFUSE Investigators. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology. 2005; 65(8): 1175–1178.
    CrossRefPubMed
  85. Fiehler J, Albers GW, Boulanger JM, et al. MR STROKE Group. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke. 2007; 38(10): 2738–2744.
    CrossRefPubMed
  86. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999; 30(1): 34–39.
    CrossRefPubMed
  87. Lindsberg PJ, Soinne L, Roine RO, et al. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke. 2003; 34(6): 1443–1449.
    CrossRefPubMed
  88. Bruno A, Levine SR, Frankel MR, et al. NINDS rt-PA Stroke Study Group. Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial. Neurology. 2002; 59(5): 669–674.
    CrossRefPubMed
  89. Yong M, Kaste M. Dynamic of hyperglycemia as a predictor of stroke outcome in the ECASS-II trial. Stroke. 2008; 39(10): 2749–2755.
    CrossRefPubMed
  90. Lyrer PA, Fluri F, Gisler D, et al. Renal function and outcome among stroke patients treated with IV thrombolysis. Neurology. 2008; 71(19): 1548–1550.
    CrossRefPubMed
  91. Naganuma M, Koga M, Shiokawa Y, et al. Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry. Cerebrovasc Dis. 2011; 31(2): 123–129.
    CrossRefPubMed
  92. Chao TH, Lin TC, Shieh Y, et al. Intracerebral hemorrhage after thrombolytic therapy in acute ischemic stroke patients with renal dysfunction. Eur Neurol. 2013; 70(5–6): 316–321.
    CrossRefPubMed
  93. Agrawal V, Rai B, Fellows J, et al. In-hospital outcomes with thrombolytic therapy in patients with renal dysfunction presenting with acute ischaemic stroke. Nephrol Dial Transplant. 2010; 25(4): 1150–1157.
    CrossRefPubMed
  94. Power A, Epstein D, Cohen D, et al. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke. Cerebrovasc Dis. 2013; 35(1): 45–52.
    CrossRefPubMed
  95. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001; 57(9): 1603–1610.
    CrossRefPubMed
  96. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003; 107(4): 598–603.
    CrossRefPubMed
  97. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke. 2003; 34(1): 40–46.
    CrossRefPubMed
  98. Castellanos M, Leira R, Serena J, et al. Plasma Cellular-Fibronectin Concentration Predicts Hemorrhagic Transformation After Thrombolytic Therapy in Acute Ischemic Stroke. Stroke. 2004; 35(7): 1671–1676.
    CrossRef
  99. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke. 2004; 35(9): 2123–2127.
    CrossRefPubMed
  100. Trouillas P, Derex L, Philippeau F, et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke. 2004; 35(6): 1323–1328.
    CrossRefPubMed
  101. Matosevic B, Knoflach M, Werner P, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology. 2013; 80(13): 1216–1224.
    CrossRefPubMed
  102. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke. 2007; 38(9): 2491–2495.
    CrossRefPubMed
  103. Millan M, Sobrino T, Castellanos M, et al. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke. 2007; 38(1): 90–95.
    CrossRefPubMed
  104. Micieli G, Marcheselli S, Tosi PA. Safety and efficacy of alteplase in the treatment of acute ischemic stroke. Vasc Health Risk Manag. 2009; 5(1): 397–409.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel. +48 58 320 94 94, faks +48 58 320 94 60, e-mail: viamedica@viamedica.pl